Negotiated product pricing

FIND negotiates preferential pricing with diagnostics suppliers for the public sector in low- and middle-income countries (LMICs). The public sector in eligible countries is defined as:

  • Governments or government-funded institutions such as health ministries, associated hospitals, armed forces, or prison services in those countries;
  • NGOs and UN-related organizations working for or in eligible countries such as the International Organization for Migration (IOM) and UNICEF;
  • Not-for-profit organizations such as Médecins Sans Frontières, Save-the-Children, OXFAM and the International Committee of the Red Cross (ICRC);
  • Global health funding mechanisms such as the Global Drug Facility, UNITAID, PEPFAR, USAID and the Global Fund, and agencies based outside the country but supporting implementation locally in the country, such as the U.S. Centers for Disease Control and Prevention and the International Union Against Tuberculosis and Lung Disease.

Any health provider intending to use negotiated prices as part of a for-profit model is required to ensure that consumers in LMICs can access affordable products. Therefore the mark-up should not exceed 20% of the negotiated preferential price, which does not include insurance or transportation. Any proposed exceptions to this require discussion and agreement with the manufacturer.

The eligibility for negotiated pricing of private organizations recognized by a country’s health ministry and whose mission is in line with humanitarian principles, such as private charities and/or private hospitals and clinics, will be decided on a case-by-case basis by the manufacturer in consultation with local and global stakeholders.

x
x

BACTEC & MGIT

Negotiated products & service prices
Negotiated reagent & accessory prices
Additional costs
Implementation
Eligible countries
Purchase orders & contact

High-throughput LAMP

porvair-logo42T-logoFIND, the London Hospital of Tropical Diseases, 42 Technology and Porvair Sciences have developed a simple, automated, high-throughput sample processing kit. It can be easily transported in a carrying case, and it can process and evaluate up to 96 samples in less than two hours with minimal hands-on time required. The kit can use whole blood samples or dried blood spot samples.

Processing kit
Equipment set
Negotiated prices
Purchase orders & contact
Implementation support
Eligible countries
Negotiated prices
Installation, training, maintenance, warranty
HumaLoop T - training video
Eligible countries
About eligible countries
Purchase orders & inquiries

Microcoat - HRP2

Microcoat Biotechnologie GmbH and FIND have worked in cooperation to develop three histidine-rich proteins (HRP2, types A, B and C), expressed as recombinant proteins in a heterologous system. These proteins are commercially available as stabilized and standardized reference materials for researchers, diagnostics developers and users of malaria rapid diagnostic tests.

The proteins can be used for evaluating the performance of malaria rapid diagnostic tests in quality control programmes and for the calibration of HRP2 detection assays.

 

Product pricing
Contact

Quick links

Positive Control Wells

Download flyer

In collaboration with FIND, Microcoat has developed a simple, field-adapted method to evaluate the quality and validity of marketed malaria rapid diagnostic tests (RDTs) based on HRP2 detection.

Malaria RDTs provide a reliable malaria diagnosis method in remote areas and clinics. However, variability in test performance has been documented, which might be due to poor manufacture or to exposure to high temperatures during transport and storage. The vital importance of accuracy in diagnosing malaria, a potentially fatal disease, makes it essential to guarantee product quality.

Product information
Purchase orders & inquiries
Negotiated price
Purchase orders & inquiries
Eligible countries

Launched in 2012, FIND and Alere/Standard Diagnostics (SD) have developed a rapid diagnostic test (RDT) to screen for gambiense HAT that is cheap and easy to use. Our priority was to develop a method for accurate screening of HAT among populations at risk. Working with many partners, a prototype RDT was developed and evaluated on more than 14,000 participants in Angola, the Democratic Republic of the Congo and the Central African Republic. The test is inexpensive, accurate, easy to use and provides results in 15 minutes. It can be used in resource-poor health facilities, requires no electricity and only minimal training of health care workers.

Currently in development, a second generation RDT is expected to be available in 2017. Partnering with the University of Dundee and SD, FIND is working to drive down the price of testing: the second generation RDT uses recombinant antigens, which are cheaper to produce and easier to standardize than the native antigens used for the first generation test.

Negotiated price
Eligible countries
Purchase orders & contact
Negotiated prices
Warranty
System maintenance
Eligible countries
About eligible countries
Purchase orders & inquiries

ZeptoMetrixTM malaria Pf  culture panels

ZeptoMetrix Corporation and FIND have produced the first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of histidine rich protein 2 (HRP2).

The ZeptoMetrix malaria P. falciparum culture panels, which are available in a range of concentrations from six different malaria strains, are intended for use by researchers and test developers to evaluate the performance of malaria rapid diagnostic tests.

Product pricing & resources
Purchase orders & inquiries